All Outputs (3)

Clinical utility of reverse phase protein array for molecular classification of breast cancer (2015)
Journal Article
Negm, O. H., Muftah, A. A., Aleskandarany, M. A., Hamed, M. R., Ahmad, D. A., Nolan, C. C., …Green, A. R. (2016). Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Research and Treatment, 155(1), 25-35. https://doi.org/10.1007/s10549-015-3654-2

Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formal... Read More about Clinical utility of reverse phase protein array for molecular classification of breast cancer.

Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer (2015)
Journal Article
Abduljabbar, R., Al-Kaabi, M. M., Negm, O. H., Jerjees, D., Muftah, A. A., Mukherjee, A., …Rakha, E. (2015). Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Research and Treatment, 150(3), 511-522. https://doi.org/10.1007/s10549-015-3348-9

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways (2015)
Journal Article
Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Alkaabi, M., Hameed, M. R., …Rakha, E. A. (2015). The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 150(1), 91-103. https://doi.org/10.1007/s10549-015-3308-4

The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investiga... Read More about The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.